×

CymaBay Therapeutics Inc.

NAS: CBAY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 18, 2019, 5:27 p.m.

/zigman2/quotes/201917619/composite

$

6.45

Change

+0.02 +0.31%

Volume

Volume 7,403

Quotes are delayed by 20 min

/zigman2/quotes/201917619/composite

Previous close

$ 6.39

$ 6.43

Change

+0.04 +0.63%

Day low

Day high

$6.16

$6.45

Open

52 week low

52 week high

$4.82

$14.00

Open

Company Description

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver di...

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Valuation

P/E Current

-5.09

P/E Ratio (with extraordinary items)

-4.93

Price to Book Ratio

2.75

Enterprise Value to EBITDA

-3.68

Efficiency

Income Per Employee

-1,687,163.00

Liquidity

Current Ratio

12.60

Quick Ratio

12.60

Cash Ratio

12.39

Profitability

Return on Assets

-49.86

Return on Equity

-56.82

Return on Total Capital

-55.46

Return on Invested Capital

-56.16

Capital Structure

Officers and Executives

Name Age Officer Since Title
Mr. Sujal Shah 44 2012 President, Chief Executive Officer & Director
Dr. Pol F. Boudes 61 2014 Chief Medical Officer
Dr. Charles A. McWherter 63 2007 Chief Scientific Officer & Senior Vice President
Dr. Patricia Rohane - 2018 Vice President-Clinical Development
Ms. Klara A. Dickinson-Eason 51 2017 Chief Regulatory & Compliance Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/07/2019 Carl Samuel Goldfischer
Director
11,675   Disposition at $9.02 per share. 105,308
02/07/2019 Carl Samuel Goldfischer
Director
9,340   Derivative/Non-derivative trans. at $5.5 per share. 51,370
02/07/2019 Carl Samuel Goldfischer
Director
2,335   Derivative/Non-derivative trans. at $5 per share. 11,675
12/21/2018 Sujal Shah
Chief Executive Officer; Director
10,000   Acquisition at $6.54 per share. 65,400
12/18/2018 Abingworth LLP
Director
53,492   Disposition at $7.43 per share. 397,445
12/17/2018 Abingworth LLP
Director
88,889   Disposition at $8.17 per share. 726,223
10/15/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $9.9 per share. 49,500
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Disposition at $13 per share. 65,000
08/29/2018 Daniel Menold
Vice President, Finance
5,000   Derivative/Non-derivative trans. at $5 per share. 25,000
07/27/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $10.9 per share. 54,500
05/11/2018 Sujal Shah
Chief Executive Officer; Director
5,000   Acquisition at $10.65 per share. 53,250
03/22/2018 Carl Samuel Goldfischer
Director
15,000   Disposition at $13.02 per share. 195,300
03/22/2018 Carl Samuel Goldfischer
Director
5,660   Derivative/Non-derivative trans. at $5.5 per share. 31,130
03/22/2018 Carl Samuel Goldfischer
Director
9,340   Derivative/Non-derivative trans. at $5 per share. 46,700
03/05/2018 Abingworth LLP
Director
13,353   Disposition at $15.51 per share. 207,105
/news/latest/company/us/cbay

MarketWatch News on CBAY

  1. CymaBay Therapeutics started at buy with $14 stock price target at Stifel Nicolaus

    7:45 a.m. June 25, 2019

    - Tomi Kilgore

  2. CymaBay Therapeutics stock price target cut to $7 from $11 at B. Riley FBR

    12:15 p.m. June 17, 2019

    - Tomi Kilgore

  3. CymaBay Therapeutics upgraded to strong buy from market outperform at Raymond James

    7:27 a.m. June 12, 2019

    - Tomi Kilgore

  4. CymaBay Therapeutics started at neutral with $9 stock price target at B. Riley FBR

    10:08 a.m. Feb. 6, 2019

    - Tomi Kilgore

  5. CymaBay Therapeutics reiterated as buy at SunTrust Robinson Humphrey

    8:46 a.m. Dec. 31, 2018

    - Ciara Linnane

  6. 4 charts to watch as tech stocks rebound

    12:18 p.m. Feb. 14, 2018

    - Harry Boxer

  7. CymaBay Therapeutics started at outperform with $35 stock price target at Evercore ISI

    8:40 a.m. Feb. 13, 2018

    - Tomi Kilgore

  8. Harry Boxer’s momentum stocks to watch this week

    11:12 a.m. Oct. 25, 2017

    - Harry Boxer

  9. CymaBay Therapeutics started at buy with $15 stock price target at SunTrust RH

    7:35 a.m. Aug. 18, 2017

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cbay

Other News on CBAY

  1. Eli Lilly And Baricitinib In PBC: What's The Story?

    3:47 p.m. July 10, 2019

    - Seeking Alpha

  2. Stifel likes Viking Therapeutics in premarket analyst action

    8:25 a.m. June 25, 2019

    - Seeking Alpha

  3. CymaBay +2.8% on new Buy rating at Stifel

    5:20 p.m. June 24, 2019

    - Seeking Alpha

  4. CymaBay Therapeutics (CBAY) Gets a Buy Rating from H.C. Wainwright

    12:22 p.m. June 12, 2019

    - SmarterAnalyst

  5. SYBX, MAT among premarket gainers

    9:16 a.m. June 12, 2019

    - Seeking Alpha

  6. CymaBay +4.8% as Raymond James fades 45% sell-off

    5:32 p.m. June 11, 2019

    - Seeking Alpha

  7. Healthcare tops midday movers

    12:41 p.m. June 11, 2019

    - Seeking Alpha

  8. Loading more headlines...

At a Glance

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard

Suite 110

Newark, California 94560

Phone

1 5102938800

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

N/A

Net Income

$-72.55M

Employees

43.00

/news/pressrelease/company/us/cbay

Press Releases on CBAY

  1. Loading more headlines...
Link to MarketWatch's Slice.